Published in J Urol on March 17, 2011
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J Clin Oncol (2014) 3.64
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
The prostate health index selectively identifies clinically significant prostate cancer. J Urol (2014) 2.68
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. Urology (2012) 1.44
The impact of baseline [-2]proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol (2013) 1.22
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. J Urol (2015) 1.13
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One (2013) 1.09
Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng/mL range. World J Urol (2012) 1.03
Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol (2013) 1.03
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration. J Urol (2012) 1.00
Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00
Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs. Prostate (2013) 0.98
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol (2014) 0.97
Emerging PSA-based tests to improve screening. Urol Clin North Am (2014) 0.94
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Screening for prostate cancer: early detection or overdetection? Annu Rev Med (2011) 0.92
The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. Nat Rev Clin Oncol (2016) 0.91
Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis. Sci Rep (2014) 0.91
Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Rev Urol (2015) 0.91
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol (2014) 0.91
Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen. Int J Clin Oncol (2014) 0.91
The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol (2014) 0.89
Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature. Korean J Urol (2014) 0.84
Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One (2014) 0.83
How Precisely Can Prostate Cancer Be Managed? Int Neurourol J (2016) 0.83
The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? World J Urol (2014) 0.83
Genetic association of the KLK4 locus with risk of prostate cancer. PLoS One (2012) 0.82
Personalized management in low-risk prostate cancer: the role of biomarkers. Prostate Cancer (2012) 0.82
Current early diagnostic biomarkers of prostate cancer. Asian J Androl (2014) 0.81
Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J Androl (2015) 0.79
The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urol Clin North Am (2016) 0.79
Prostate cancer biomarkers: Are we hitting the mark? Prostate Int (2016) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Future prospects in the diagnosis and management of localized prostate cancer. ScientificWorldJournal (2013) 0.77
PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer. Turk J Urol (2014) 0.77
Urinary Volatile Organic Compounds for the Detection of Prostate Cancer. PLoS One (2015) 0.77
Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol (2015) 0.77
Novel biomarkers for the detection of prostate cancer. J Clin Urol (2016) 0.77
RNA biomarkers to facilitate the identification of aggressive prostate cancer. Mol Aspects Med (2015) 0.76
Immunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate Cancer. J Cancer (2016) 0.76
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer. Biomed Res Int (2015) 0.76
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int (2016) 0.76
Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Asian J Androl (2016) 0.75
Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination. Investig Clin Urol (2016) 0.75
Morbidity and psychological impact of prostate biopsy: the future calls for a change. Asian J Androl (2014) 0.75
Prostate cancer: Prostate Health Index--improving screening in men with family history. Nat Rev Urol (2013) 0.75
Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance. Can Urol Assoc J (2016) 0.75
Author reply: The neutrophil-to-lymphocyte ratio in clinical practice. Can Urol Assoc J (2016) 0.75
Screening and Detection of Prostate Cancer-Review of Literature and Current Perspective. Indian J Surg Oncol (2017) 0.75
From bench to bedside: the realities of reducing global prostate cancer disparity in black men. Ecancermedicalscience (2014) 0.75
Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers. PLoS One (2016) 0.75
The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population. Sci Rep (2016) 0.75
Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). EJIFCC (2014) 0.75
Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements. Sci Rep (2016) 0.75
Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. Int J Mol Sci (2016) 0.75
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer. Urol Case Rep (2016) 0.75
Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice. Prostate Cancer Prostatic Dis (2017) 0.75
Improving prediction models with new markers: a comparison of updating strategies. BMC Med Res Methodol (2016) 0.75
Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017. Curr Opin Urol (2017) 0.75
[-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report. BMC Urol (2016) 0.75
Utilization of individualized prostate cancer and genomic biomarkers for the practicing urologist. Rev Urol (2017) 0.75
PSA and Prostate Health Index based prostate cancer screening in a hereditary migration complicated population: implications in precision diagnosis. J Cancer (2017) 0.75
The role of prostate cancer biomarkers in undiagnosed men. Curr Opin Urol (2017) 0.75
Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL. Int J Nanomedicine (2017) 0.75
Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark (2017) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 8.14
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem (1991) 2.96
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem (2004) 1.85
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. Urology (2003) 1.46
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol (2004) 1.44
Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology (2002) 1.41
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol (2003) 1.40
Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res (2009) 1.26
A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology (1997) 1.26
Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem (2010) 1.17
Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol (2008) 1.12
Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology (2005) 1.11
Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol (2005) 1.09
Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology (2003) 1.05
New confidence intervals for the difference between two sensitivities at a fixed level of specificity. Stat Med (2006) 1.05
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet (2006) 5.65
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol (2012) 4.48
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol (2002) 4.13
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Contemporary diagnosis and management of renal angiomyolipoma. J Urol (2002) 3.41
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res (2008) 3.35
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology (2006) 3.34
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol (2012) 3.34
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia. Urology (2013) 3.31
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol (2012) 3.07
Delay of surgery in men with low risk prostate cancer. J Urol (2011) 3.05
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 2.85
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol (2005) 2.84
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
The increasing incidence of newborn circumcision: data from the nationwide inpatient sample. J Urol (2005) 2.76
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review. Eur Urol (2008) 2.66
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol (2003) 2.59
Lifestyle-only intervention attenuates the inflammatory state associated with obesity: a randomized controlled study in adolescents. J Pediatr (2005) 2.55
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53
Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 2.51
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol (2010) 2.47